Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment

Bristol Myers Squibb, Exelixis Granted FDA Priority Review For Kidney Cancer Treatment

Bristol Myers Squibb and Exelixis announced Monday that the FDA had granted priority review for their combined treatment for a form of advanced kidney cancer; and BMY stock, EXEL stock rose.